Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028
Dyne Therapeutics (DYN) reported a wider Q3 2026 net loss of $193.6M ($1.06 per share) due to higher R&D and administrative expenses. Cash reserves are $1.134B, expected to last into Q2 2028. The company's z-rostudirsen BLA is under FDA priority review, with a PDUFA date of January 21, 2027. Topline ACHIEVE trial data for z-basivarsen are expected in Q1 2027. DYN stock is trading at $18.23, down 1.78%.



